Trump’s Vision to Eradicate Cancer: Harnessing AI, Deregulation, and Biotech Innovation for a Cure

In a awesome episode of The Megyn Kelly Show (above), host Megyn Kelly sat down with biotech pioneer Dr. Patrick Soon-Shiong to discuss a groundbreaking approach to preventing and curing cancer. Soon-Shiong, the CEO of the Los Angeles Times Media Group and inventor of the cancer drug Abraxane, outlined his “bioshield” platform—a biologic treatment already FDA-approved for other uses that boosts the body’s natural immune defenses to combat cancer at its roots. He revealed past conversations with President Donald Trump, including a recent push for Trump to expedite its rollout by slashing bureaucratic red tape. “If President Trump could oversee some sort of a medical protocol that prevents cancer and cures cancer… It would absolutely cement his legacy,” Soon-Shiong told Kelly, emphasizing how Trump’s leadership could make this accessible nationwide.

This interview, aired in October 2025, underscores Trump’s evolving plan to tackle cancer, blending deregulation, artificial intelligence (AI), and innovative therapies. As of October 9, 2025, Trump’s administration has already taken concrete steps, including a September executive order prioritizing AI for pediatric cancer cures. Critics argue these efforts come amid funding cuts, but proponents see a streamlined, efficient path to victory over one of humanity’s deadliest foes. Here’s how Trump’s plan could work, drawing on the latest developments. At the heart of Trump’s strategy is a renewed focus on leveraging American innovation to outpace cancer, moving beyond traditional government-heavy approaches like the Biden-era Cancer Moonshot. On September 30, 2025, Trump signed an executive order titled “Unlocking Cures for Pediatric Cancer with Artificial Intelligence,” directing federal agencies to harness AI for faster drug discovery, personalized treatments, and data-driven research.

• Is Ivermectin the Key to Fighting Cancer? …. – Wellness (Dr. McCullough’s company) Sponsored Post 🛑 You can get MEBENDAZOLE  and Ivermectin from Wellness 👍

This builds on his first-term promises to “cure cancer” and allocates an additional $50 million to AI initiatives at the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH). The order mandates collaboration with private-sector tech giants, aiming to analyze vast datasets from clinical trials, genetic profiles, and patient outcomes to identify patterns humans might miss. For instance, AI could simulate millions of drug interactions in hours, accelerating the timeline from lab to patient by years. This AI push is particularly targeted at pediatric cancers, which affect about 15,000 children annually in the U.S. and have seen stagnant survival rates for certain types like brain tumors.

Trump’s plan envisions AI as a “force multiplier,” integrating machine learning with genomic sequencing to tailor therapies. A White House fact sheet highlights how AI could “transform the Nation’s current care and research approach,” potentially reducing trial costs by 50% and improving outcomes through predictive modeling. HHS has already doubled AI-backed funding for childhood cancer to $100 million, partnering with companies like IBM and Google to develop algorithms that detect early-stage tumors via imaging or blood tests. Experts like Dr. Soon-Shiong argue this aligns perfectly with innovations like his bioshield, which targets the p53 gene—a tumor suppressor often mutated in cancers. By using AI to analyze p53 interactions, treatments could be optimized for prevention, especially in high-risk groups like those with Lynch syndrome.

• Be prepared for anything, including lockdowns with your own Emergency Med kit – see Wellness Emergency Kit (includes Ivermectin and other essential drugs, guide book, much more… peace of mind for you and your family) 🛑 – Dr. McCullough’s company! – Sponsor

Deregulation is another pillar, addressing Soon-Shiong’s frustration with FDA bottlenecks. Trump’s order calls for expedited reviews of AI-assisted therapies, echoing his first-term Operation Warp Speed that delivered COVID vaccines in record time. In the Kelly interview, Soon-Shiong detailed how his bioshield—already in Phase III trials for lung, breast, and pancreatic cancers—faces $200-300 million per trial hurdles despite promising results, such as 100% response rates in small head and neck cancer cohorts. Trump’s plan could work by granting “priority review” status to such biologics, potentially halving approval times. This is crucial amid rising cancer rates: A 2025 Lancet Oncology report anticipates shifts in U.S. cancer care under Trump, including reduced drug costs via price transparency and pharmacy benefit reforms, making treatments more accessible.

• How can you move your 401K to Gold penalty free? Get the answer and more with Goldco’s exclusive Gold IRA Beginner’s Guide. Click here now! – Goldco

• The Truth About Weight Loss After 40 – Wellness Can Help You – Sponsor

A New York Times exposé from September 2025 detailed canceled grants, arguing it “shuts down the war on cancer.” However, supporters counter that these are efficiency measures, redirecting funds from redundant studies to AI-driven breakthroughs. Trump’s EO explicitly boosts pediatric funding, and a Politico report notes it’s “powered by energy” innovations, like advanced computing, to fuel AI without environmental trade-offs. If successful, this could mirror Warp Speed’s success, where public-private partnerships yielded rapid results. Real-world examples bolster optimism. AI tools like PathAI and Tempus are already diagnosing cancers with 95% accuracy, reducing misdiagnoses.

Soon-Shiong’s protocol, with trials at Mayo Clinic showing extended survival in glioblastoma patients (8-10 months post-treatment), could scale nationally under Trump’s deregulation. Combined with Kennedy’s focus on root causes—like COVID’s potential p53 suppression—the plan addresses both cure and prevention. A 2025 Reuters analysis projects AI could cut childhood cancer mortality by 20% within a decade if fully implemented. Social media buzz, including X posts, reflects growing excitement. One user hailed the plan as a “game-changer,” while another tied it to Trump’s legacy. Challenges remain: Ethical AI use, data privacy, and equitable access. Yet, Trump’s track record—defeating ISIS, brokering Abraham Accords—suggests bold action yields results. In essence, Trump’s plan leverages AI’s predictive power, biotech like bioshield, and streamlined regulations to attack cancer on multiple fronts. By fostering innovation over bureaucracy, it could deliver cures faster, saving millions. As Soon-Shiong told Kelly, “One man can make that available”—and with Trump’s resolve, America might just win the war on cancer.